Abstract:Transcriptional modulation by histone acetylation and deacetylation is mediated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), which are critical components in balancing many physiological and pathological processes. The aberrant transcriptional repression caused by abnormal expression of HDAC is believed to be able to act as master regulators of many diseases,including cancer. HDAC inhibitors (HDACIs) currently in clinical trials have shown activity and represented a class of molecularly targeted anti-tumour agents with potential for efficacy based on a novelmechanism of action. This review introduces (1) the crystallographic structure of a histone deacetylasesanalogue——HDLP; (2) the mechanism, classification, quantitative structure-activity relationship (QSAR) ,research background and current status of HDACIs; (3) developing advances and strategies of CS055,a lead compound of Chipscreen.

New Development of HDAC Inhibitors As Anti-Cancer Agents